Filing Flows › Comparisons › LGN vs RUN
Legence vs Sunrun: LGN and RUN compared
Legence is the larger company: $1.3B of revenue in its latest quarter (Q2 2026) against $1.1B for Sunrun (Q3 2026). Legence is growing faster (+111% against +52% a year earlier). Sunrun is more profitable, with an operating margin of 14.0% against -0.5%.
Where the money goes: LGN and RUN
Legence (LGN) · Q2 2026
Legence, Q2 2026: revenue $1.3B (+111% year over year), operating margin -0.5%, net loss $34.6M, operating cash flow $74.4M. The chart follows the revenue to costs, profit and cash.
Sunrun (RUN) · Q3 2026
Sunrun, Q3 2026: revenue $1.1B (+52% year over year), operating margin 14.0%, net earnings $153M, operating cash flow $301M. The chart follows the revenue to costs, profit and cash.
| Legence (LGN) | Sunrun (RUN) | |
|---|---|---|
| Latest quarter | Q2 2026 | Q3 2026 |
| Revenue | $1.3B | $1.1B |
| Revenue growth, Y/Y | +111% | +52% |
| Operating margin | -0.5% | 14.0% |
| Net earnings | −$34.6M | $153M |
| Net margin | -2.7% | 13.9% |
| Operating cash flow | $74.4M | $301M |
| Free cash flow | $50.3M | — |
| Market value | $2.2B | $2.7B |
| P/E | — | 5.0× |
| Analysts’ mean target | $94.35 | $13.82 |
Where the revenue comes from
Legence
- Installation & Maintenance: $1.1B (84%)
- Engineering & Consulting: $207M (16%)
Sunrun
- Customer agreements and incentives: $553M (50%)
- Energy systems and product sales: $546M (50%)
Questions
Which is bigger, Legence or Sunrun?
Legence is the larger company: $1.3B of revenue in its latest quarter (Q2 2026) against $1.1B for Sunrun (Q3 2026).
Is Legence or Sunrun growing faster?
Legence is growing faster (+111% against +52% a year earlier).
Which is more profitable, Legence or Sunrun?
Sunrun is more profitable, with an operating margin of 14.0% against -0.5%.
More: Legence earnings · how Legence makes money · Sunrun earnings · how Sunrun makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Aug 13, 2026; 10-Q filed Nov 4, 2026). Fiscal quarters can end on different dates. Not investment advice.